ArticleBreast cancer research and treatment2026

Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer.

Yasmin Leshem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.